| Literature DB >> 29245978 |
Liang-Tseng Kuo1,2, Su-Ju Lin3, Chi-Lung Chen1, Pei-An Yu1, Wei-Hsiu Hsu1,4, Tien-Hsing Chen5.
Abstract
Diabetes and chronic kidney disease (CKD) are associated with a higher rate of complications in patients undergoing total knee arthroplasty (TKA). The purpose of this study was to determine the effects of CKD and diabetes in patients after TKA. Diabetic patients who received unilateral primary TKA between January 2008 and December 2011 were enrolled. The follow-up period was more than 6 months. The primary outcome was a TKA-related infection and the secondary outcome was all-cause mortality. The study cohort included 13844 patients who were followed for a mean period of 2 years, of whom 1459 (10.5%) had CKD. The patients with CKD were older than those without CKD (71.6 versus 70.3 years, P<0.0001) and had higher rates of hypertension, gouty arthritis, ischemic heart disease, chronic pulmonary obstructive disease, pulmonary embolism and deep vein thrombosis (all P<0.0001). After adjustment of comorbidities, the CKD group had a higher incidence of urinary tract infections (OR: 1.61, 95% CI: 1.19-2.17). There were no significant differences in wound infections, pneumonia, pulmonary embolism or in-hospital death between the two groups. After adjustment of confounders, the CKD group had higher rates of myocardial infarction (HR: 2.06, 95% CI: 1.26-3.39) and mortality (HR: 1.99, 95% CI: 1.59-2.48). The risk of TKA-related infection during follow-up was comparable between the two groups (HR: 1.31, 95% CI: 0.94-1.82). In conclusion, CKD is associated with increased risks of urinary tract infections, myocardial infarction and all-cause mortality after TKA. Surgeons should be aware of this when evaluating TKA patients with renal disease.Entities:
Keywords: chronic kidney disease; diabetes mellitus; mortality; periprosthetic joint infection; total knee arthroplasty
Year: 2017 PMID: 29245978 PMCID: PMC5725020 DOI: 10.18632/oncotarget.22215
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The enrollment of the study subjects
Characteristics of the study cohort
| Variable | CKD ( | Non-CKD ( | |
|---|---|---|---|
| Age, Mean ( | 71.6 (7.6) | 70.3 (7.6) | <0.0001* |
| Age group | |||
| < 65 years | 241 (16.5) | 2466 (19.9) | <0.0001* |
| 65-74 years | 718 (49.2) | 6386 (51.6) | |
| ≥ 75 years | 500 (34.3) | 3533 (28.5) | |
| Gender | |||
| Male | 477 (32.7) | 2738 (22.1) | <0.0001* |
| Female | 982 (67.3) | 9647 (77.9) | <0.0001* |
| Comorbidity | |||
| Hypertension | 1305 (89.4) | 10140 (81.9) | <0.0001* |
| Dyslipidemia | 611 (41.9) | 5159 (41.7) | 0.8703 |
| Gouty arthritis | 366 (25.1) | 1262 (10.2) | <0.0001* |
| Cirrhosis | 31 (2.1) | 165 (1.3) | 0.0154* |
| Ischemic heart disease | 421 (28.9) | 2740 (22.1) | <0.0001* |
| Rheumatoid arthritis | 50 (3.4) | 380 (3.1) | 0.4550 |
| COPD | 128 (8.8) | 685 (5.5) | <0.0001* |
| Immune disease | 67 (4.6) | 466 (3.8) | 0.1193 |
| Malignancy | 99 (6.8) | 552 (4.5) | <0.0001* |
| Pulmonary embolism | 5 (0.3) | 4 (0.0) | <0.0001* |
| Deep vein thrombosis | 15 (1.0) | 51 (0.4) | 0.0012* |
| Cerebral vascular accident | 145 (9.9) | 1046 (8.5) | 0.0545 |
| Follow up (years) | 1.9 (1.0) | 2.1 (1.0) | <0.0001* |
CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; SD = standard deviation.
* P value < 0.05.
In-hospital complications
| Variable | CKD ( | Non-CKD ( | CKD vs. Non-CKD OR (95% CI)a | |
|---|---|---|---|---|
| Pneumonia | 4 (0.3) | 28 (0.2) | 0.91 (0.31–2.68) | 0.8670 |
| Urinary tract infection | 54 (3.7) | 310 (2.5) | 1.61 (1.19–2.17) | 0.0020* |
| Acute PJI | 5 (0.3) | 60 (0.5) | 0.73 (0.29–1.83) | 0.4979 |
| In hospital death | 2 (0.1) | 7 (0.1) | 1.53 (0.30–7.74) | 0.6075 |
PJI = periprosthetic joint infection; OR = odds ratio; CI = confidence interval.
a Variables listed in Table 1 (except for follow up year) were adjusted.
* P value < 0.05.
Outcomes after discharge of the index admission
| Variables | CKD ( | Non-CKD ( | CKD vs. Non-CKD HR (95% CI)b | |
|---|---|---|---|---|
| Superficial wound infection | 14 (1.0) | 93 (0.8) | 1.27 (0.71–2.26) | 0.4252 |
| PJI requiring debridement | 30 (2.1) | 210 (1.7) | 1.18 (0.77–1.80) | 0.4397 |
| PJI requiring implants removal | 8 (0.6) | 35 (0.3) | 1.76 (0.80–3.85) | 0.1601 |
| Any PJI | 43 (3.0) | 283 (2.3) | 1.31 (0.94–1.82) | 0.1133 |
| Pulmonary embolism | 2 (0.1) | 34 (0.3) | 0.43 (0.10–1.80) | 0.2479 |
| Deep vein thrombosis | 13 (0.9) | 117 (0.9) | 0.77 (0.44–1.34) | 0.3540 |
| Cerebral vascular accident | 67 (4.6) | 447 (3.6) | 1.13 (0.87–1.47) | 0.3661 |
| Acute myocardial infarction | 22 (1.5) | 75 (0.6) | 2.06 (1.26–3.39) | 0.0043* |
| Major adverse cardiac eventa | 89 (6.1) | 531 (4.3) | 1.24 (0.98–1.56) | 0.0678 |
| In 90 days | 252 (17.3) | 1,291 (10.4) | 1.52 (1.32–1.75) | <0.0001* |
| At the last follow up | 814 (55.8) | 5,507 (44.5) | 1.39 (1.28–1.50) | <0.0001* |
| In 90 days | 15 (1.0) | 37 (0.3) | 2.55 (1.35–4.80) | 0.0038* |
| At the last follow up | 110 (7.5) | 439 (3.5) | 1.99 (1.59–2.48) | <0.0001* |
PJI = periprosthetic joint infection; HR = hazard ratio; CI = confidence interval.
a Any one of the cardiac outcomes.
b Variables listed in Table 1 (except for follow-up years) were adjusted.
* P value < 0.05.
Figure 2Cumulative incidence of PJI
Patients with CKD tended to have a higher cumulative incidence of PJI than those without CKD, although the difference was not statistically significant (P=0.0748, competing risk survival model).
Figure 3Time to the cumulative incidence of PJI
Superficial wound infections developing earlier than PJIs requiring surgical procedures (median time, 4.7 months versus 10 months).